Memorial Sloan Kettering Cancer Center (MSKCC) is an NCl-designated Comprehensive Cancer Center with one of the largest hematopoietic stem cell transplant ( HSCT) programs in the country. The SCT program at MSKCC is a FACT-accredited program and is divided into pediatric and adult services. MSKCC has been a Core Member of the BMT-CTN since it's inception and Dr. Giralt as the new Chief of the Adult BMT Service as well as all members of the Adult BMT Service consider participation in the BMT-CTN an integral part of their mission. GVHD, both acute and chronic remains one ofthe most significant barriers to successful HSCT. Even when effectively treated the sequelae of GVHD or the side effects of chronic immune-suppressive therapy have significant negative impact on the quantity and quality of life of transplant survivors. Thus prevention of both acute and chronic GVHD should remain a major element in the BMT-CTN research portfolio. Only two acute GVHD prevention strategies have been shown to reduce the risk of chronic GVHD, T cell depletion (TCD) and post transplant cyclophosphamide (post transplant CY). For this BMT-CTN renewal application we hypothesize that TCD will be more effective than post transplant CY in preventing aGVHD and cGVHD after HLA matched HSCT in patients with AML or MDS and that these strategies differ in regards to immune-reconstitution and quality of life. We propose to demonstrate this through the conduction of a randomized phase II trial whose specific aims are: 1. Demonstrate that 6 month event free survival (6mEFS) (events being defined as death, relapse, non-engraftment, grade 3-4 aGVHD or extensive cGVHD) is superior for recipients of a TCD transplant than those receiving post transplant CY, when either is used as a CNl free GVHD prevention strategy. 2. Compare infection rates, toxicities and immune-reconstitution kinetics between transplant recipients receiving either TCD or post transplant CY. 3. Compare longitudinal symptom burden profiles among stem cell transplant recipients receiving either TCD or post transplant CY as GVHD prophylaxis.

Public Health Relevance

The proposed trial will confirm the impact of immune-reconstitution on transplant outcomes. This will also be the largest study looking at longitudinal symptom burden in the setting of allogeneic HSCT. Data obtained from this study will be pooled together with other symptom burden studies to explore the potential relationship between genetic factors and development of symptom clusters.

National Institute of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Special Emphasis Panel (ZHL1-CSR-K (M3))
Program Officer
Di Fronzo, Nancy L
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Sloan-Kettering Institute for Cancer Research
New York
United States
Zip Code
D'Souza, Anita; Pasquini, Marcelo; Logan, Brent et al. (2017) Heavy/light chain ratio normalization prior to transplant is of independent prognostic significance in multiple myeloma: a BMT CTN 0102 correlative study. Br J Haematol 178:816-819
Scott, Bart L; Pasquini, Marcelo C; Logan, Brent R et al. (2017) Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes. J Clin Oncol 35:1154-1161
Steering Committee Of The Blood And Marrow Transplant Clinical Trials Network (2016) The Blood and Marrow Transplant Clinical Trials Network: An Effective Infrastructure for Addressing Important Issues in Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant 22:1747-1757
Devine, Steven M; Owzar, Kouros; Blum, William et al. (2015) Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncolo J Clin Oncol 33:4167-75
Giralt, Sergio; Garderet, Laurent; Durie, Brian et al. (2015) American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Tra Biol Blood Marrow Transplant 21:2039-2051
Appelbaum, Frederick R; Anasetti, Claudio; Antin, Joseph H et al. (2015) Blood and marrow transplant clinical trials network state of the Science Symposium 2014. Biol Blood Marrow Transplant 21:202-24
Tamari, Roni; Chung, Stephen S; Papadopoulos, Esperanza B et al. (2015) CD34-Selected Hematopoietic Stem Cell Transplants Conditioned with Myeloablative Regimens and Antithymocyte Globulin for Advanced Myelodysplastic Syndrome: Limited Graft-versus-Host Disease without Increased Relapse. Biol Blood Marrow Transplant 21:2106-2114
Alsina, Melissa; Becker, Pamela S; Zhong, Xiaobo et al. (2014) Lenalidomide maintenance for high-risk multiple myeloma after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 20:1183-9
Yanik, Gregory A; Horowitz, Mary M; Weisdorf, Daniel J et al. (2014) Randomized, double-blind, placebo-controlled trial of soluble tumor necrosis factor receptor: enbrel (etanercept) for the treatment of idiopathic pneumonia syndrome after allogeneic stem cell transplantation: blood and marrow transplant clinical trials ne Biol Blood Marrow Transplant 20:858-64
Kemeny, Nancy E; Chou, Joanne F; Capanu, Marinela et al. (2014) KRAS mutation influences recurrence patterns in patients undergoing hepatic resection of colorectal metastases. Cancer 120:3965-71

Showing the most recent 10 out of 15 publications